Abstract
Diabetes mellitus is considered a cardiovascular disease owing to its prevalent association with cardiovascular morbidity and mortality. Cardiovascular events are not only more frequent but also complicated with more severe outcomes in diabetic patients as compared with non-diabetic patients. One mechanism accounting for this difference consists of the impairment of the regenerative cellular machinery, which contributes to tissue healing. Recent evidence indicates the contribution of resident progenitor cells in post-ischemic tissue remodeling. In addition, a wide spectrum of cells from distant sources, including the bone marrow, is attracted and home to the healing tissue. Diabetes affects the process of mobilization and recruitment as well as intrinsic functional properties of bone marrow-derived progenitor cells. This review highlights current evidence for diabetes-induced damage of bone marrow hematopoietic progenitor cells in the endosteal and vascular niches.
Keywords: Bone marrow, diabetes, ischemia, microenvironment, osteoblastic niche, stem cells, vascular niche
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Volume: 12 Issue: 2
Author(s): Giuseppe Mangialardi, Atsuhiko Oikawa, Carlotta Reni and Paolo Madeddu
Affiliation:
Keywords: Bone marrow, diabetes, ischemia, microenvironment, osteoblastic niche, stem cells, vascular niche
Abstract: Diabetes mellitus is considered a cardiovascular disease owing to its prevalent association with cardiovascular morbidity and mortality. Cardiovascular events are not only more frequent but also complicated with more severe outcomes in diabetic patients as compared with non-diabetic patients. One mechanism accounting for this difference consists of the impairment of the regenerative cellular machinery, which contributes to tissue healing. Recent evidence indicates the contribution of resident progenitor cells in post-ischemic tissue remodeling. In addition, a wide spectrum of cells from distant sources, including the bone marrow, is attracted and home to the healing tissue. Diabetes affects the process of mobilization and recruitment as well as intrinsic functional properties of bone marrow-derived progenitor cells. This review highlights current evidence for diabetes-induced damage of bone marrow hematopoietic progenitor cells in the endosteal and vascular niches.
Export Options
About this article
Cite this article as:
Mangialardi Giuseppe, Oikawa Atsuhiko, Reni Carlotta and Madeddu Paolo, Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (2) . https://dx.doi.org/10.2174/187153012800493530
DOI https://dx.doi.org/10.2174/187153012800493530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Strategies Combining Biomaterials and Stem Cells for Bone, Liver and Skin Regeneration
Current Stem Cell Research & Therapy The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Adynamic Ileus Induced by Varenicline
Current Drug Safety Tacrolimus Toxicity Reverses the Inhibitory Effects of Renin Angiotensin System Blockade on PAI-1 Expression in Cardiac Tissue
Current Enzyme Inhibition Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine Proteomics Can Help to Gain Insights into Metabolic Disorders According to Body Reserve Availability
Current Medicinal Chemistry The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design HIV-1 Latency and Eradication: Past, Present and Future
Current HIV Research Structure and Enzymatic Activities of Human Serum Albumin
Current Pharmaceutical Design